Drug Trial Radar · NCT07876128
A Clinical Trial of MK-2750 in Participants With Advanced Solid Tumors (MK-2750-002)
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Nov 16, 2026
Primary completion
Apr 12, 2029
Study completion May 30, 2031
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Oct 15, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
MK-2750 is a trial medicine designed to treat certain solid tumors. MK-2750 is a type of treatment called an antibody drug conjugate (ADC). ADCs attach to a protein on cancer cells and deliver medicine to destroy those cells. The goals of this trial are to learn: * About the safety of MK-2750 and if participants tolerate it. Tolerate means participants will receive trial treatment in the trial unless they need to stop it due to health problems. * How many participants have cancer respond (get smaller or go away) to MK-2750
Conditions
- Advanced Solid Tumors
- Malignant Neoplasm
Interventions
MK-2750Biological
Administered as an intravenous (IV) infusion
5-HT3 serotonin receptor antagonistDrug
Administered as a premedication per the approved product label
NK-1 receptor antagonistDrug
Administered as a premedication per the approved product label
CorticosteroidDrug
Administered as a premedication per the approved product label
Steroid mouthwash (dexamethasone or equivalent)Drug
Administered orally per the approved product label as a rescue medication
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 2 years
- Number of Participants Who Discontinued Study Intervention Due to an AETime frame: Up to approximately 2 years
- Objective Response Rate (ORR)Time frame: Up to approximately 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.